U.S. markets closed
  • S&P 500

    4,577.10
    +64.06 (+1.42%)
     
  • Dow 30

    34,639.79
    +617.75 (+1.82%)
     
  • Nasdaq

    15,381.32
    +127.27 (+0.83%)
     
  • Russell 2000

    2,206.33
    +58.91 (+2.74%)
     
  • Crude Oil

    67.18
    +0.68 (+1.02%)
     
  • Gold

    1,770.30
    +7.60 (+0.43%)
     
  • Silver

    22.38
    +0.06 (+0.29%)
     
  • EUR/USD

    1.1306
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.4480
    +0.0140 (+0.98%)
     
  • GBP/USD

    1.3299
    -0.0003 (-0.02%)
     
  • USD/JPY

    113.1000
    -0.1090 (-0.10%)
     
  • BTC-USD

    56,648.48
    -224.67 (-0.40%)
     
  • CMC Crypto 200

    1,442.69
    +3.81 (+0.26%)
     
  • FTSE 100

    7,129.21
    -39.47 (-0.55%)
     
  • Nikkei 225

    27,691.98
    -61.39 (-0.22%)
     

Nemaura Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Loughborough, England, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that Chief Executive Officer Faz Chowdhury, Ph.D. will present at the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually from September 13 – 15, 2021.

Dr. Chowdhury will deliver his corporate presentation, which will become available beginning on September 13 at 7:00 AM ET.

Investors can register here: www.hcwevents.com.

Mr. Chowdhury will also be available for one-on-one meetings throughout the conference.

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Contact:

Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com